Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: A case control study

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Takahashi, Shunsaku ^a   Miura, Norimasa ^a   Harada, Tomomi ^a   Wang, ZhongZhi ^a   Wang, Xinhui ^a   Tsubokura, Hideyuki ^b   Oshima, Yoshiaki ^a,c   Hasegawa, Junichi ^a   Inagaki, Yoshimi ^a   Shiota, Goshi ^d  

^a TOTTORI UNIVERSITY   (Japan)

^b Tottori Red Cross Hospital   (Japan)

^c SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; MUCIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIVELESTAT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; VON WILLEBRAND FACTOR; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE STORM; DISEASE SEVERITY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; NUCLEOTIDE SEQUENCE; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; BLOOD; ESOPHAGUS TUMOR; GENETICS; MIDDLE AGED;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYTOKINES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; MALE; MIDDLE AGED; MUCIN-1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; VON WILLEBRAND FACTOR;

EID: 77958046889     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-103     Document Type: Article

References (51)

1. Milberg JA, Davis DR, Steinberg KP, et al. Improved survival of patients with acute respiratory distress syndrome: 1983-1993. JAMA 1995, 273:306-309. 10.1001/jama.273.4.306, 7815658.
2. Lewandowski K, Metz J, Deutschmann C, et al. Incidence, severity, and mortality of acute respiratory distress syndrome. Am J Respir Crit Care Med 1995, 151:1121-1125.
3. Mink SN, Light RB, Cooligan T. Effect of PEEP on gas exchange and pulmonary perfusion in canine lobar pneumonia. J Appl Physiol 1981, 50:517-523.
4. Nahum A, Hoyt J, Schmitz L, et al. Effect of mechanical ventilation strategy on dissemination of intratracheally instilled Escherichia coli in dogs. Crit Care Med 1997, 25:1733-1743. 10.1097/00003246-199710000-00026, 9377891.
5. Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758. 10.1001/jama.286.14.1754, 11594901.
6. Tang BM, McLean AS, Dawes IW, et al. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009, 37:882-888. 10.1097/CCM.0b013e31819b52fd, 19237892.
7. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med 2005, 11(2):56-63. 10.1016/j.molmed.2004.12.007, 15694867.
8. Chen XQ, Bonnefoi H, Pelte MF, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000, 6:3823-3826.
9. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002, 48:1647-1653.
10. Miura N, Hasegawa J, Shiota G. Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol 2008, 2:511-527.
11. Miura N, Kabashima H, Shimizu M, et al. Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis. Hepatol Int 2008, 2:213-221. 10.1007/s12072-008-9053-6, 2716859, 19669307.
12. Wong FH, Huang CY, Su LJ, et al. Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma. Int J Oncol 2009, 34:117-128.
13. El-Kenawy A, Lotfy M, El-Kott A, et al. Significance of matrix metalloproteinase 9 and CD34 expressions in esophageal carcinoma: correlation with DNA content. J Clin Gastroenterol 2005, 39:791-794. 10.1097/01.mcg.0000177244.59591.c3, 16145342.
14. Gu ZD, Li JY, Li M, Gu J, et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 2005, 100:1835-1843. 10.1111/j.1572-0241.2005.50018.x, 16086722.
15. Ngiam N, Post M, Kavanagh BP. Early growth response factor-1 in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1089-1091. 10.1152/ajplung.00265.2007, 17766585.
16. Hoetzel A, Dolinay T, Vallbracht S, et al. Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. Am J Respir Crit Care Med 2008, 177:1223-32. 10.1164/rccm.200708-1265OC, 2408440, 18356564.
17. Ingram JL, Antao-Menezes A, Mangum JB, et al. Opposing actions of Stat1 and Stat6 on IL-13-induced up-regulation of early growth response-1 and platelet-derived growth factor ligands in pulmonary fibroblasts. J Immunol 2006, 177:4141-4148.
18. El Gazzar M, Yoza BK, Chen X, et al. Chromatin-specific remodeling by HMGB1 and linker histone H1 silence proinflammatory genes during endotoxin tolerance. Mol Cell Biol 2009, 2655606, 19158276.
19. Kornblit B, Munthe-Fog L, Madsen HO, et al. Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit Care 2008, 12:R83. 10.1186/cc6935, 2481482, 18577209.
20. Suda K, Kitagawa Y, Ozawa S, et al. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery?. Dis Esophagus 2006, 19:5-9. 10.1111/j.1442-2050.2006.00529.x, 16364036.
21. Nakashima T, Yokoyama A, Ohnishi H, et al. Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med 2008, 263:432-439. 10.1111/j.1365-2796.2008.01929.x, 18298483.
22. Sato H, Callister ME, Mumby S, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J 2004, 23:142-145. 10.1183/09031936.03.00070303, 14738246.
23. Guillem P, Billeret V, Buisine MP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 2000, 88:856-861. 10.1002/1097-0215(20001215)88:6<856::AID-IJC3>3.0.CO;2-D, 11093805.
24. Busso N, Karababa M, Nobile M, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 2008, 3:e2267. 10.1371/journal.pone.0002267, 2377336, 18493620.
25. Van Gool F, Gallí M, Gueydan C, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med 2009, 15:206-210. 10.1038/nm.1906, 2845476, 19151729.
26. Rongvaux A, Galli M, Denanglaire S, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008, 181:4685-4695.
27. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14:1431-1437. 358498, 8289818.
28. Li J, Hoyle GW. Overexpression of PDGF-A in the lung epithelium of transgenic mice produces a lethal phenotype associated with hyperplasia of mesenchymal cells. Dev Biol 2001, 239:338-349. 10.1006/dbio.2001.0441, 11784039.
29. Gowan SE, Grossmann RE, Kimani PW, et al. Platelet-derived growth factor receptor-alpha-expressing cells localize to the alveolar entry ring and have characteristics of myofibroblasts during pulmonary alveolar septal formation. Anat Rec (Hoboken) 2008, 291:1649-1661.
30. Aizawa K, Suzuki T, Kada N, et al. Regulation of platelet-derived growth factor-A chain by Krüppel-like factor 5: new pathway of cooperative activation with nuclear factor-kappaB. J Biol Chem 2004, 279:70-76. 10.1074/jbc.M306621200, 14573617.
31. Budinger GR, Chandel NS, Donnelly HK, et al. Active transforming growth factor-beta1 activates the procollagen I promoter in patients with acute lung injury. Intensive Care Med 2005, 31:121-128. 10.1007/s00134-004-2503-2, 15565360.
32. Fahy RJ, Lichtenberger F, McKeegan CB, et al. The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am J Respir Cell Mol Biol 2003, 28:499-503. 10.1165/rcmb.2002-0092OC, 12654639.
33. Wu HP, Chen CK, Chung K, et al. Plasma transforming growth factor-beta1 level in patients with severe community-acquired pneumonia and association with disease severity. J Formos Med Assoc 2009, 108:20-27. 10.1016/S0929-6646(09)60028-0, 19181604.
34. Ware LB. Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design. Crit Care Med 2005, 33:S217-222. 10.1097/01.CCM.0000155788.39101.7E, 15753731.
35. Russell J. Genetics of coagulation factors in acute lung injury. Crit Care Med 2003, 31:S243-7. 10.1097/01.CCM.0000057870.61079.3E, 12682447.
36. Hamacher J, Lucas R, Lijnen HR, et al. Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2002, 166:651-656. 10.1164/rccm.2109004, 12204860.
37. Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001, 29:2325-2331. 10.1097/00003246-200112000-00016, 11801836.
38. Flori HR, Ware LB, Milet M, et al. Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med 2007, 8:96-101. 10.1097/01.PCC.0000257097.42640.6F, 17273112.
39. García-Fernández N, Montes R, Purroy A, et al. Hemostatic disturbances in patients with systemic inflammatory response syndrome (SIRS) and associated acute renal failure (ARF). Thromb Res 2000, 100:19-25. 10.1016/S0049-3848(00)00306-6, 11053612.
40. Fujihashi K, Kono Y, Kiyono H. Effect of IL6 on B cells in mucosal immune response and inflammation. Res Immunol 1992, 143(7):744-749. 10.1016/0923-2494(92)80015-D, 1439148.
41. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
42. Bones RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
43. Miura N, Shiota G, Nakagawa T, et al. Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology 2003, 64:430-434. 10.1159/000070303, 12759542.
44. Miura N, Maeda Y, Kanbe T, et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 2005, 11:3205-3209. 10.1158/1078-0432.CCR-04-1487, 15867214.
45. Miura N, Nakamura H, Sato R, et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 2006, 97:1366-1373. 10.1111/j.1349-7006.2006.00342.x, 17052260.
46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
47. Vincent J, Ferreira F, Moreno R. Scoring systems for assessing organ dysfunction and survival. Crit Care Clin 2000, 16:353-366. 10.1016/S0749-0704(05)70114-7, 10768086.
48. Wright CD, Kucharczuk JC, O'Brien SM, et al. Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model; Society of Thoracic Surgeons General Thoracic Surgery Database. J Thorac Cardiovasc Surg 2009, 137(3):587-595. 10.1016/j.jtcvs.2008.11.042, 19258071.
49. Vincent J, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319.
50. Urschel JD. Esophagogastrostomy anastomotic leaks complicating esophagectomy: a review. Am J Surg 1995, 169(6):634-40. 10.1016/S0002-9610(99)80238-4, 7771633.
51. Bouadma L, Luyt C, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417.